Chimerix

Incorporated in 2000, Chimerix is a biopharmaceutical company committed to the discovery, development, and commercialization of novel oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need. Our proprietary technology has led us to brincidofovir (CMX001), a clinical-stage nucleotide analog lipid conjugate that has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. Brincidofovir has shown in vitro activity against all five families of DNA viruses that affect humans, including CMV, adenovirus, BK virus and herpes simplex viruses.

We believe that antivirals that could reduce the frequency of these and other DNA viruses and potentially avoid increasing the risk of other opportunistic infections could provide measureable clinical and pharmacoeconomic benefits for patients and the healthcare system. Through work to date, we see significant opportunities to apply the lipid conjugate technology to other disease categories that are also characterized by a need for effective treatments.